Emgality demonstrated a consistent safety profile across six Phase 3 studies in migraine and episodic cluster headache (N=3724)1-4
Lilly continues to monitor the safety data of Emgality in the general population.
Download savings cards to help eligible patients on Emgalityc
cGovernmental beneficiaries excluded; terms and conditions apply.
Discover what Emgality can do for your patients with 4 or more unpredictable MHDs per month1
References:
- Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
- Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:90. doi:10.1186/s12883-020-1609-7.
- Mulleners WM, Kim B, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814-825.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0107.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0008.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0007.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0026.
- Oakes TM, Kovacs R, Rosen N, et al. Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache. 2020;60:110-123.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0165.
- Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi:10.1186/s12883-018-1193-2.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0137.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0139.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0140.